Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Mar 31, 2011
Filed with the SEC on May 6, 2011 and accepted by EDGAR at May 6, 2011, 20:18 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2011-03-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2011-01-01 to 2011-03-31 | $73.7m | us-gaap:Revenues |
| Research and development | 3 months2011-01-01 to 2011-03-31 | $158.6m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2011-01-01 to 2011-03-31 | $71.5m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2011-01-01 to 2011-03-31 | −$159.9m | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2011-01-01 to 2011-03-31 | $12.0m | us-gaap:InterestExpense |
| Diluted EPS | 3 months2011-01-01 to 2011-03-31 | −$0.87 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2011-01-01 to 2011-03-31 | −$0.87 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2011-01-01 to 2011-03-31 | 202,329,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 3 months2011-01-01 to 2011-03-31 | −$186.6m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 3 months2011-01-01 to 2011-03-31 | $4.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2011-03-31 | $446.5m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2011-03-31 | $873.0m | us-gaap:AssetsCurrent |
| Total assets | At period end2011-03-31 | $1.54bn | us-gaap:Assets |
| Current liabilities | At period end2011-03-31 | $416.2m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2011-03-31 | $1.15bn | us-gaap:Liabilities |
| Long-term debt | At period end2011-03-31 | $105.0m | us-gaap:LongTermDebt |
| Shareholders' equity | At period end2011-03-31 | $391.7m | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
Source: SEC EDGAR, the filing index for accession 0001047469-11-004721. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.